Screener / SEC EDGAR /CIK 0001582313 /10-K filed Feb 26, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Xenon Pharmaceuticals Inc. XENE

Compare with peers Embed
SEC comment letters, last 20 years

3 reviews of XENE's filings by SEC staff

UPLOAD and CORRESP
Reviews 3 latest letter Sep 22, 2014
Questions asked 68 each answered in the company's own letter
No closing letter 3 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 5 UPLOAD
  2. 2. Questions in them 68 numbered comments
  3. 3. Company replies 6 CORRESP
  4. 4. Reviews closed 0 of 3 closing letter

Form S-1

2014-09-22 to 2014-11-03 · 5 questions · 2 letters from the SEC, 6 from the company
No closing letter
Strategic Alliances · Agreement with uniQure for Glybera, page 108
SEC asked (1)
We note your revised disclosure in response to our prior comment 2 which states that the royalties under the agreement with uniQure are payable until the expiration of the last licensed patent from UBC. Please revise your disclosure regarding the royalty term to provide the expiration date of the last licensed patent from UBC.
XENE answered
The Company respectfully advises the Staff that, as disclosed on page 112 of the Registration Statement, the latest expiration date of the in-licensed patents from UBC is June 2020 (absent any extensions of term) and the latest expiration date of the in-licensed patent applications from UBC is expected to be 2020 (absent any extensions of term).
Rest of the answer

Accordingly, absent any extensions of the relevant patent terms, the license agreement with UBC shall expire in 2020, upon which the uniQure agreement is also expected to terminate.

Furthermore, regarding the expiration of the royalty terms under the agreement with uniQure, the Company respectfully submits that, as discussed in the Company’s response to comment 5 to the Staff’s letter dated October 4,

Page

2013, licensed patents under the UBC agreement include several patents that are in various stages of prosecution in numerous countries and the terms of which could be extended. Accordingly, providing estimated durations of the royalty terms under the uniQure agreement based on an anticipated year of expiration of the UBC in-licensed patents brings with it a significant likelihood of inaccurately reflecting the actual royalty term as, for example, certain patent applications may not issue and additional patents may be filed that fall within the scope of the UBC agreement. Given the potential changes in the term of the UBC in-licensed patents and other related uncertainties, the

Company respectfully submits that disclosure of the year that a royalty term expires would not be helpful to an investor and could potentially be misleading.

Read in the reply
Agreements with Genentech for GDC-0276 and Selective Inhibitors of…, page 110
SEC asked (2)
We note your disclosure which states that on March 2014, you entered into an additional agreement with Genentech for pain genetics. Please expand your disclosure to describe the material terms of the agreement, including the parties’ rights and obligations, duration, termination provisions, and any royalties within a ten percent range (e.g., single digits, teens, twenties, etc…).
Rest of the question

Also, please file the agreement as an exhibit pursuant to Item 601(b)(10) of Regulation S-K.

XENE answered
to the Staff’s comment, the Company proposes to revise the disclosure on page 111 of the Registration Statement as follows in connection with its submission of an amendment to the Registration Statement (deleted language shown in strike through and added language underlined):

“In March 2014, we entered into an additional agreement with

Genentech for pain genetics, where we intend to use our Extreme Genetics discovery platform to focus on identifying genetic targets associated with rare phenotypes where individuals have an inability to perceive pain or where individuals have non-precipitated
Rest of the answer

spontaneous severe pain. Pursuant to the terms of this agreement, any intellectual property arising out of the collaboration will be jointly owned by us and Genentech. We have also granted Genentech a time-limited, exclusive right of first negotiation on a target-by-target basis to form joint drug discovery collaborations. Under the terms of this agreement, Genentech paid us an upfront payment of $1.5 million. In addition, and wWe are eligible for an additional $2.0 million in milestone payments. The agreement terminates upon the expiration of Genentech’s time-limited, exclusive right of first negotiation which shall be exercisable for two years. Genentech may terminate the agreement with three months advance notice anytime on or after the 12 month anniversary of the effective date of the agreement, and each party may terminate the agreement in the event of a material breach by the other party that remains uncured for 90 days., and Furthermore, at our option, a Genentech affiliate will invest up to $5.0 million in a private placement concurrent with this public offering at the same price per share as this public offering. The option to invest will expire if the public offering does not occur by December 31, 2014.”

The Company respectfully advises the Staff that, notwithstanding the foregoing, the March 2014 agreement is not material to the Company, the existing disclosure regarding the agreement, as revised above, is sufficient for an agreement of this nature and that disclosure of the additional details requested would neither be helpful to an investor nor would disclosure of such details alter the total mix of information available regarding the Company.

The March 2014 agreement was made in the ordinary course of business and the Company’s business is not substantially dependent on such agreement as the total amount which can be earned under the agreement is $3.5 million, $1.5 million of which has been received by the Company as an upfront payment. The existing description on pages 64 and 111 of the Registration Statement already provides the following details:

•

The maximum amount payable to the Company pursuant to upfront and milestone payments;

A description of the genetic target identification work the Company will perform pursuant to the agreement;

Joint ownership by the Company and Genentech for any intellectual property arising out of the collaboration; and

A grant of a time-limited, exclusive right of first negotiation to Genentech on a target-by-target basis.

Furthermore, the Company supplementally advises the Staff that the agreement does not contain any royalty provisions.

Given the foregoing details, the Company respectfully submits that the March 2014 agreement is not material to the Company, but that the disclosure provides additional evidence to investors of the Company’s execution on its strategy of forming collaborations for the advancement of its product pipeline. For the foregoing reasons, the Company believes that the new agreement with Genentech is not a material contract within the meaning of Item 601(b)(10) of Regulation S-K.

Read in the reply
Intellectual Property, page 111
SEC asked (3)
Please expand your disclosure regarding the patent applications which you co-own for GDC-0276 to identify with whom you co-own these patent applications and the foreign jurisdictions where the applications are pending.
XENE answered
to the Staff’s comment, the Company proposes to revise the disclosure on page 112 of the Registration Statement as follows in connection with its filing of an amendment to the Registration Statement (deleted language shown in strike through and added language underlined)

“As of June 30 September 30, 2014 we, together with

Genentech, co-owned two pending U.S.
Rest of the answer

patent applications, one pending PCT international patent application and three corresponding patent applications in various foreign jurisdictions Argentina, Taiwan and the

Cooperation Council for the Arab States of the Gulf relating to GDC-0276 and methods of making and using this and certain related compounds. Any patents issuing from these applications are expected to expire in 2033 (absent any extensions of term).”

Read in the reply
Principal Shareholders, page 149
SEC asked (4)
We note your updated principal shareholders table to June 30, 2014 in response to our prior comment 4. Please revise the principal shareholders table so that it is as of the latest practicable date within two weeks of the filing date of your amended the registration statement.
XENE answered
Company acknowledges the Staff’s comment and will update the principal shareholders table with its filing of an amendment to the Registration Statement so that it is as of the latest practicable date within two weeks of the filing date.
Read in the reply
Capitalization, page 55
SEC asked
On page F-17, you state “Each of the Series A, Series B and Series E preferred shares will automatically convert into common shares in connection with an IPO satisfying certain threshold requirements.” Please disclose these threshold requirements in the notes to the financial statements, and expand your pro forma disclosures throughout the filing to explain why assuming that the convertible preferred stock will be
Rest of the question

converted into common stock is factually supportable. Refer to rule 11-02(b)(6) of Regulation S-X.

XENE answered
The Company advises the Staff that it has revised the disclosure on pages F-8 and F-17 in response to the Staff’s comment.

The Company further supplementally advises the Staff that the Company has received consents from the requisite number of holders of

Series A, Series B and Series E preferred shares, as prescribed in the articles of the Company, to effect the conversion of all outstanding Series A, Series B and Series E preferred shares into common shares prior to the closing of the offering upon approval of the Company’s board of directors.
Rest of the answer

Consequently, the Company advises the Staff that there are no longer any threshold requirements that must be satisfied in order for all of

Securities and Exchange Commission

Page the outstanding Series A, Series B and Series E preferred shares to be converted into common shares. As such, the Company advises the Staff that it has revised the Registration Statement as discussed above to remove reference to the threshold requirements prior to the automatic conversion of the Company’s preferred shares to common shares.

Read in the reply

Also in this review: company letter, Sep 29, 2014, company letter, Oct 14, 2014, company letter, Oct 14, 2014, company letter, Nov 3, 2014

Form S-1

2014-04-09 to 2014-04-09 · 4 questions · 1 letter from the SEC, 0 from the company
No closing letter
SEC letter of Apr 9, 2014 ↗ no reply letter on EDGAR (the company may have answered in an amended filing)
Our Programs · Xenon’s Proprietary Product Candidates, page 4
SEC asked (1)
Please remove the disclosure under the section entitled “Xenon’s Proprietary Product Candidates” on pages 4-5. This disclosure is too preliminary to be highlighted in the prospectus summary and is already appropriately located in the Business section. Alternatively, you may replace this disclosure with a single paragraph summarizing your preclinical proprietary product candidates.
Rest of the question

If you retain the abbreviated disclosure, please revise the caption to insert the word preclinical.

XENE answered

No reply letter found.

Strategic Alliances, page 104
SEC asked (2)
We note your response to our prior comment 5. For each of the agreements with uniQure, Teva, Genentech and Merck, please explain how the royalty term is calculated, including a summary of any exceptions and variations to the term.
XENE answered

No reply letter found.

TV-45070: A Small Molecule for the Treatment of Pain · Oral TV-45070 Phase 2 Trial in EM, page 95
SEC asked (3)
We note that you have presented the first four paragraphs of this section two times on pages 95 and 96 of your filing. Please delete the repeated paragraphs from page 96.
XENE answered

No reply letter found.

Principal Shareholders, page 143
SEC asked (4)
Please revise your principal shareholders table so that it is as of the latest practicable date rather than as of December 31, 2013.
XENE answered

No reply letter found.

Form S-1

2013-09-12 to 2013-10-04 · 59 questions · 2 letters from the SEC, 0 from the company
No closing letter
Results discussion (MD&A)Critical estimatesRisk factorsRevenueExecutive payDerivatives and hedging
SEC letter of Sep 12, 2013 ↗ no reply letter on EDGAR (the company may have answered in an amended filing)
General
SEC asked (1)
Please file all exhibits as soon as practicable. We may have further comments upon examination of these exhibits.
XENE answered

No reply letter found.

General
SEC asked (2)
Prior to its use please provide us proofs of all graphic, visual or photographic information you will provide in the printed prospectus. Please note that we may have comments regarding this material.
XENE answered

No reply letter found.

General
SEC asked (3)
Please supplementally provide us with any written materials that you or anyone authorized to do so on your behalf provides in reliance on Section 5(d) of the Securities Act to potential investors that are qualified institutional buyers or institutional accredited investors.
Rest of the question

Similarly, please supplementally provide us with any research reports about you that are published or distributed in reliance upon Section 2(a)(3) of the Securities Act of 1933 added by Section 105(a) of the Jumpstart Our Business Startups Act by any broker or dealer that is participating or will participate in your offering.

XENE answered

No reply letter found.

General
SEC asked (4)
Comments to your application for confidential treatment will be delivered under separate cover.
XENE answered

No reply letter found.

Overview, page 1
SEC asked (5)
We note that you state that you have three development-stage product candidates. Please identify the two development-stage product candidates that are pre-clinical.
XENE answered

No reply letter found.

Our Programs, page 2
SEC asked (6)
We note on page 2 that uniQure is preparing to apply for regulatory approval for Glybera in the U.S. Please expand your disclosure to discuss the timeline for applying for U.S. approval. If any regulatory issues or other factors have caused uniQure to delay filing an NDA with the FDA or an NDS with Health Canada, please provide appropriate disclosure.
XENE answered

No reply letter found.

Our Programs, page 2
SEC asked (7)
The first time you refer to the terms “antisense oligonucleotide” and “hepcidin,” please explain how each functions in the human body.
XENE answered

No reply letter found.

Our Extreme Genetics Discovery Platform, page 3
SEC asked (8)
Please expand your disclosure on page 3 and 84 to discuss the differences between your Extreme Genetics discovery platform and the methods commonly used by other pharmaceutical companies that are developing products based upon isolating genes or portions of the human genome.
XENE answered

No reply letter found.

Implications of Being an Emerging Growth Company, page 6
SEC asked (9)
Please disclose your election under Section 107(b) of the Jobs Act:  If you have elected to opt out of the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the Jobs Act, include a statement that the election is irrevocable; or  If you have elected to use the extended transition period for complying with new or revised accounting standards under Section
Rest of the question

102(b) of the Jobs Act, provide a risk factor explaining that this election allows you to delay the adoption of new or revised accounting standards that have different effective dates for public and private companies until those standards apply to private companies. Please state in your risk factor that, as a result of this election, your financial statements may not be comparable to companies that comply with public company effective dates. Include a similar statement in your critical accounting policy disclosures in MD&A.

XENE answered

No reply letter found.

“Recent patent reform legislation and court decisions could increase . . .,” page 38
SEC asked (10)
Please explain specifically how the Leahy-Smith Act increases uncertainty as to any of your licensed or owned patents. Additionally, please identify any of your licensed or owned patents that may be vacated or adversely affected by the U.S. Supreme Court decision in Association for Molecular Pathology v. Myriad Genetics, Inc.
XENE answered

No reply letter found.

“We or the third parties upon whom we depend may be adversely affected . . .,” page 42
SEC asked (11)
Please clarify whether your business interruption insurance applies in the event of an earthquake.
XENE answered

No reply letter found.

Cautionary Note Regarding Forward-Looking Statements, page 49
SEC asked (12)
Please remove your statement that investors “are cautioned not to give undue weight to such estimates” and the statement that “such information is inherently imprecise.” It is not appropriate to directly or indirectly disclaim liability for information in the registration statement.
XENE answered

No reply letter found.

Use of Proceeds, page 52
SEC asked (13)
We note that you intend to use proceeds of this offering to fund the planned development of XEN701. Please expand your disclosure to state the stage of development of XEN701 you expect to reach using the allocated proceeds.
XENE answered

No reply letter found.

Dilution, page 56
SEC asked (14)
Please tell us why you are not subtracting your redeemable convertible preferred shares in your calculation of your historical net tangible book value of as of June 30, 2013.
XENE answered

No reply letter found.

Management Discussion and Analysis of Financial Condition and Results of Operations, 60
SEC asked (15)
We note on page 61 and in a risk factor on page 12 that you state that you have not generated substantial royalties on product sales. Please revise your disclosure throughout your prospectus to clarify that you have not generated any revenue from product royalties. Alternatively, please clarify and describe the royalties you have received.
XENE answered

No reply letter found.

Accrued Expenses, page 67
SEC asked (16)
Please disclose whether there have been any material adjustments to your estimates of accrued expenses for the periods presented.
XENE answered

No reply letter found.

Share-Based Compensation · Valuation of Common Shares, page 69
SEC asked (17)
We have reviewed your share-based compensation disclosures and have the following comments:  Please revise your disclosure to state the events that resulted in an increase in the fair value of the common stock from $0.55 at December 21, 2012 to $1.07 on January 1, 2013.
Rest of the question

 With respect to the January 1, 2013 valuation report, please clarify whether the blend in the income and market approaches resulted in an equal weighting of both methods.  Please update the stock option table on page 70 through the date of effectiveness of your registration statement. Also, please disclose in the filing any new equity issuances such as preferred stock, warrants, etc. through the date of effectiveness.  Please note we may have additional comments on your accounting for stock compensation and related disclosure once you have disclosed an estimated offering price. Please provide quantitative and qualitative disclosures explaining the difference between the estimated offering price and the fair value of the most recent issuance.

XENE answered

No reply letter found.

Research and Development Expenses, page 73
SEC asked (18)
For your key research and development projects please disclose the costs incurred during each period presented and to date.
XENE answered

No reply letter found.

Business, page 81
SEC asked (19)
Please amend your disclosure to describe the INDs submitted for XEN402 by indication and disclose when these INDs were filed and by whom. Additionally, please clarify whether you or anyone else has filed INDs for XEN701 or the Selective Inhibitor of Nav1.7 for the Treatment of Pain. If so, provide the same information as requested for the INDs for XEN402.
XENE answered

No reply letter found.

Glybera, page 82
SEC asked (20)
Please disclose how you anticipate physicians will prescribe Glybera for patients suffering from LPLD. In particular, please clarify whether you believe doctors will prescribe Glybera for permanent, indefinite, intermittent or short-term use.
XENE answered

No reply letter found.

Programs, page 85
SEC asked (21)
We note that you have a collaboration agreement with Teva to develop XEN402 as an inhibitor of Nav1.7. We also note that you have entered into a collaboration agreement with Genentech to develop inhibitors for Nav1.7. Please expand your disclosure to discuss the differences between these two drugs that both inhibit Nav1.7, and the anticipated patient population for each.
XENE answered

No reply letter found.

Glybera (alipogene tiparvovec): A Gene Therapy for the Orphan Disease LPLD, page 85
SEC asked (22)
We note on page 85 that you state that you are eligible to receive a double-digit percentage of all compensation received by uniQure. Please revise this disclosure to provide narrower information about the percentage. For example, you may either provide a range of percentages within ten percent or a statement that the percentage is in the teens, twenties, etc.
Rest of the question

Additionally, we note that you state that you are eligible to receive mid-single digit royalties from uniQure on page 97. Please include this disclosure on page 85.

XENE answered

No reply letter found.

Glybera (alipogene tiparvovec): A Gene Therapy for the Orphan Disease LPLD, page 85
SEC asked (23)
Please quantify the size of the patient population that you and your collaborators are targeting for sales of Glybera.
XENE answered

No reply letter found.

Glybera (alipogene tiparvovec): A Gene Therapy for the Orphan Disease LPLD, page 85
SEC asked (24)
Please clarify whether Glybera has orphan designation in the EU.
XENE answered

No reply letter found.

Glybera (alipogene tiparvovec): A Gene Therapy for the Orphan Disease LPLD, page 85
SEC asked (25)
We note that you state the results of your Topical XEN402 Phase 2 Trial in EM on page 89. Please indicate the statistical significance of your results by providing a p-value.
XENE answered

No reply letter found.

XEN701: An Antisense Oligonucleotide for the Treatment of Anemia of Chronic Kidney · Disease, page 94
SEC asked (26)
Please quantify the size of the patient population that you plan to target for sales of XEN701.
XENE answered

No reply letter found.

Programs in Discovery, page 96
SEC asked (27)
Please quantify the size of the patient population suffering from DS that you plan to target for sales of your small-molecule sodium channel modulators.
XENE answered

No reply letter found.

Strategic Alliances, page 97
SEC asked (28)
We note that you have a license agreement with Memorial University of Newfoundland on page 76. Please disclose the material terms of this agreement under a separate caption, including the patents licensed under this agreement and how they apply to your products, the duration, material termination provisions, and payment terms and prior payments.
Rest of the question

Additionally, please file this agreement as an exhibit pursuant to Item 601(b)(10) of Regulation S-K. Alternatively, please provide us with an analysis supporting your determination that this agreement is not material to the company.

XENE answered

No reply letter found.

Strategic Alliances, page 97
SEC asked (29)
Please disclose under a separate caption the payment terms, duration, and material termination provisions of your agreement with the University of British Columbia for your license related to Glybera.
XENE answered

No reply letter found.

Agreement with uniQure for Glybera, page 97
SEC asked (30)
For the uniQure agreement, please disclose the duration of the agreement, the material termination provisions, and when the licensed patents expire.
XENE answered

No reply letter found.

Agreement with uniQure for Glybera, page 97
SEC asked (31)
We note that you state you will receive a double-digit percentage of all non-royalty compensation that uniQure receives from sublicenses. Please revise your disclosure throughout the registration statement to provide narrower information about the percentage. For example, you may either provide a range of percentages within ten percent or a statement that the percentage is in the teens, twenties, etc.
XENE answered

No reply letter found.

Agreement with Teva for XEN402, page 98
SEC asked (32)
For the Teva agreement, please disclose the amount of the opt-in fee required for you to have a minority co-promotion interest, the resulting share of the operating profits that you are entitled, and the duration of the agreement. Additionally, please revise your disclosure throughout the registration statement to provide narrower information about the royalty provisions.
Rest of the question

For example, you may either provide a range of royalties within ten percent or a statement that the percentage is in the teens, twenties, etc.

XENE answered

No reply letter found.

Agreement with Genentech for Selective Inhibitors of Nav1.7, page 99
SEC asked (33)
Please state the duration of your agreement with Genentech.
XENE answered

No reply letter found.

Agreement with Genentech for Selective Inhibitors of Nav1.7, page 99
SEC asked (34)
For the Genentech Agreement, we note that you are eligible to receive royalties in the low double-digit range. Please revise your disclosure throughout the registration statement to provide narrower information about the royalty provisions. For example, you may either provide a range of royalties within ten percent or a statement that the percentage is in the teens, twenties, etc.
XENE answered

No reply letter found.

Agreement with Merck for Cardiovascular Disease, page 99
SEC asked (35)
For the Merck Agreement, we note that you are eligible to receive royalties in the high single digit to low double-digit range. Please revise your disclosure regarding the lowdouble digit range throughout the registration statement to provide narrower information about the royalty provisions.
Rest of the question

For example, you may refer to a range of royalties within ten percent or state that that the percentage is in the teens, twenties, etc.

XENE answered

No reply letter found.

Agreement with Merck for Cardiovascular Disease, page 99
SEC asked (36)
Please state the duration of the agreement with Merck.
XENE answered

No reply letter found.

Research and Development, page 101
SEC asked (37)
Please estimate the amount spent on research and development for the past 3 years ending in December 31, 2012 as required by Regulation S-K Item 101(c)(1)(xi).
XENE answered

No reply letter found.

Manufacturing, page 102
SEC asked (38)
We note that there are a limited number of suppliers of XEN701, and the inability to find a suitable replacement could materially impact your business. Please expand your disclosure to state your current relationship and the material termination provision of your contractual agreement with your suppliers for XEN701. Additionally, file these agreements as exhibits pursuant to Item 601(b)(10) of Regulation S-K.
XENE answered

No reply letter found.

Orphan Drug Designation, page 107
SEC asked (39)
Please clarify if the FDA has granted orphan designation to any of your products.
XENE answered

No reply letter found.

Government Regulation Outside of the U.S., page 109
SEC asked (40)
Please clarify if any of your products have received orphan designation in the EU.
XENE answered

No reply letter found.

Management · Executive Officers, page 115
SEC asked (41)
Please expand your disclosure to include Gary Bridger’s business experience between December 2007 and June 2010.
XENE answered

No reply letter found.

Indemnification Agreements and Directors’ and Officers’ Liability Insurance, page 123
SEC asked (42)
We note that you will enter into indemnification agreements. Please file the form of these agreements as an exhibit pursuant to Item 601(b)(10) of Regulation S-K.
XENE answered

No reply letter found.

Indemnification Agreements and Directors’ and Officers’ Liability Insurance, page 123
SEC asked (43)
Please expand your disclosure to explain the limits of indemnification permitted under Canadian law.
XENE answered

No reply letter found.

Executive Compensation · Executive Employment Arrangements, page 125
SEC asked (44)
Please update your disclosure to include the material terms of the executive employees’ amended employment agreements when available.
XENE answered

No reply letter found.

Executive Compensation · Executive Employment Arrangements, page 125
SEC asked (45)
Please file the amended employment agreements between the company and each of Dr. Pimstone and Dr. Goldberg as exhibits pursuant to Item 601(b)(10) of Regulation S-K.
XENE answered

No reply letter found.

Certain Relationships and Related Party Transactions · Consulting Services Provided by Genworks, Inc., page 132
SEC asked (46)
If you have a written consulting agreement with Genworks, Inc., please file the agreement as an exhibit pursuant to Item 601(b)(10) of Regulation S-K.
XENE answered

No reply letter found.

Shares Eligible for Future Sale, page 149
SEC asked (47)
Please state the number of shares of common stock that will be restricted securities under Rule 144 upon completion of this offering.
XENE answered

No reply letter found.

Shares Eligible for Future Sale, page 149
SEC asked (48)
Once available please file copies of each of the lock-up agreements. Notes to Financial Statements 9. Redeemable Convertible Preferred Shares:
XENE answered

No reply letter found.

Conversion, page F-16
SEC asked (49)
With respect to the certain adjustments, please revise your disclosure to specifically state the additional events that cause the conversion rate to change, as your reference to “the like” is ambiguous. In addition, please provide us an analysis of whether the conversion option for all preferred stock issued should be a derivative liability. 11. Stock Option Plan, page F-17
XENE answered

No reply letter found.

Conversion, page F-16
SEC asked (50)
We note that the expected volatility remained at 70% for each of the periods presented. Please tell us why the amount did not change for any period and provide us with your calculation. In addition, clarify how you determined that each public companies used in your determination of expected volatility company was similar. Please also tell us whether the volatility was consistently calculated for each period (i.e.
Rest of the question

daily, monthly, weekly, etc.). 13. Collaboration Agreements, page F-20

XENE answered

No reply letter found.

Conversion, page F-16
SEC asked (51)
For your Genome BC arrangement, please revise you disclosure to comply with ASC 605-25-50-2. It is currently unclear what you are collaborating on and what your deliverables are. In addition, please tell us what the counterparty is receiving for funding your research and development beyond the subscription rights.
Rest of the question

If the consideration is limited to the subscription rights, please explain the economics of the arrangement to us.

XENE answered

No reply letter found.

Conversion, page F-16
SEC asked (52)
For your Genentech and Teva arrangements please disclose why the licenses did not qualify as separate units of accounting pursuant to ASC 605-25-50-2f. In addition, tell us how your statement that you are unable to estimate a fair value for the undelivered items complies with ASC 605-25-30-2 and how this statement impacts your accounting.
XENE answered

No reply letter found.

Conversion, page F-16
SEC asked (53)
You disclose several agreements which you are eligible to receive milestone payments. Please revise your disclosure to describe each substantive milestone and the related contingent consideration for each agreement separately. Refer to ASC 605-28-50-2b.
Rest of the question

In addition, clarify for us why you believe all potential milestone payments under the Merck and Teva agreement are substantive per ASC 605-28-25-2 when you do not appear to be performing any additional work in the Merck agreement and it is unclear why sales milestones are substantive in the Teva agreement. If you intend to respond to these comments with an amended draft registration statement, please submit it and any associated correspondence in accordance with the guidance we provide in the Division’s October 11, 2012 announcement on the SEC website at http://www.sec.gov/divisions/corpfin/cfannouncements/drsfilingprocedures101512.htm. Please keep in mind that we may publicly post filing review correspondence in accordance with our December 1, 2011 policy (http://www.sec.gov/divisions/corpfin/cfannouncements/edgarcorrespondence.htm). If you intend to use Rule 83 (17 CFR 200.83) to request confidential treatment of information in the correspondence you submit on EDGAR, please properly mark that information in each of your confidential submissions to us so we do not repeat or refer to that information in our comment letters to you.

XENE answered

No reply letter found.

SEC letter of Oct 4, 2013 ↗ no reply letter on EDGAR (the company may have answered in an amended filing)
“Recent patent reform legislation and court decisions could increase . . .,” page 39
SEC asked (1)
We note your response to our prior comment 10. Please expand your disclosure to identify the sections of the Leahy-Smith Act that increases uncertainty with respect to your owned and licensed patents in the U.S., and explain the reasons for the increased uncertainty caused by these sections of the Leahy-Smith Act.
XENE answered

No reply letter found.

Critical Accounting Policies and Significant Judgments and Estimates · Valuation of Common Shares, page 71
SEC asked (2)
Please refer to your response to our comment 17 and address the following:  Please disclose the weighting of the income and market approach for the June 30, 2013 valuation and tell us how you determined that the weighting for this valuation and the January 1, 2013 valuation was appropriate given the company’s stage of development. Also tell us if there were significant differences between the two approaches.
Rest of the question

 Please note we may have additional comments on your accounting for stock compensation and related disclosure once you have disclosed an estimated offering price.

XENE answered

No reply letter found.

Business · Approved Product, page 84
SEC asked (3)
We note on page 85 that uniQure is planning to apply for regulatory approval for Glybera. Additionally, we note that uniQure plans to file an IND with the FDA in the first half of 2014. Please note that the filing for an IND should not be characterized as applying for regulatory approval, which language suggests that the company is making an NDA filing.
Rest of the question

If uniQure is making an NDA filing, please revise your disclosure accordingly. If uniQure is filing an IND, please state the phase of testing that uniQure expects to start with given that Glybera is already approved in the EU. Please make corresponding changes throughout the prospectus where you include similar disclosure.

XENE answered

No reply letter found.

Topical XEN402 Phase 2 Trial in EM, page 92
SEC asked (4)
We note your response to our prior comment 25 and the inclusion of the p-values in the table on page 93. Please also state in this section that the cooling frequency and cooling duration results did not meet the test of statistical significance.
XENE answered

No reply letter found.

Strategic Alliances, page 101
SEC asked (5)
We note your disclosure of the Agreements with each of uniQure, Teva, Isis, Genentech, and Merck. For each of these agreements, please explain how the royalty term is calculated. Additionally, please state the year each of these royalty terms would expire given the patents that are currently outstanding. Notes to Financial Statements 11. Stock Option Plan, page F-18
XENE answered

No reply letter found.

Strategic Alliances, page 101
SEC asked (6)
Please refer to your response to our comment 50. Several of the companies that you are using in your calculation of historical volatility have product revenues, and do not appear to be similar in size or market capitalization to the Company.
Rest of the question

Please revise your calculation of historical volatility to exclude these companies or confirm that there would not be a material difference in the volatility and stock based compensation expense for each of the periods presented if these companies were excluded. If you intend to respond to these comments with an amended draft registration statement, please submit it and any associated correspondence in accordance with the guidance we provide in the Division’s October 11, 2012 announcement on the SEC website at http://www.sec.gov/divisions/corpfin/cfannouncements/drsfilingprocedures101512.htm. Please keep in mind that we may publicly post filing review correspondence in accordance with our December 1, 2011 policy (http://www.sec.gov/divisions/corpfin/cfannouncements/edgarcorrespondence.htm). If you intend to use Rule 83 (17 CFR 200.83) to request confidential treatment of information in the correspondence you submit on EDGAR, please properly mark that information in each of your confidential submissions to us so we do not repeat or refer to that information in our comment letters to you.

XENE answered

No reply letter found.

Letters without questions

Other letters

UPLOAD and CORRESP
7 other letters: notices that a filing will not be reviewed, requests to declare a registration effective, and the like
  • Jun 9, 2020 · SEC: will not review the filing · Xenon Pharmaceuticals Inc. · Registration Statement on Form S-3 · Filed June 3, 2020 ·...
  • Jun 10, 2020 · XENE: letter to the SEC · Xenon Pharmaceuticals Inc. (the “Company”) · Registration Statement on Form S-3 ·...
  • Aug 13, 2019 · XENE: letter to the SEC · Xenon Pharmaceuticals Inc. (the “Company”) · Registration Statement on Form S-3 ·...
  • Aug 12, 2019 · SEC: will not review the filing · Xenon Pharmaceuticals Inc. · Registration Statement on Form S-3 · Filed August 6, 2019...
  • Dec 30, 2015 · XENE: letter to the SEC · Xenon Pharmaceuticals Inc. (the “Company”) · Registration Statement on Form S-3 ·...
  • Dec 10, 2015 · SEC: will not review the filing · Xenon Pharmaceuticals Inc. · Registration Statement on Form S-3 · Filed December 7,...
  • Sep 24, 2014 · XENE: letter · Xenon Pharmaceuticals Inc. · Registration Statement on Form S-1 · Filed · September...

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 18 letters filed since 2013-09-12. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/XENE/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.